Artificial Intelligence

The Singaporean facilities firm lands major residential deals, bolstering its recurring revenue as it navigates financial headwinds with a push in AI robotics.

Genius Sports and NBC are rolling out AI-powered ads in NBA games. Is it the future of fan engagement or a new level of commercial intrusion?

A consulting firm's work optimizing ORs and sterile processing impacted over 1 million patients, revealing the crucial link between logistics and patient care.

Banuba's new AI Talking Photo API promises to revolutionize video creation, but the rise of lifelike digital avatars also fuels a critical ethical debate.

Nautilus Biotechnology cuts losses and preps its Voyager platform for a late 2026 launch, targeting the next frontier in neurodegenerative disease research.

Infrastructure software giant posts 11% revenue growth, outlines a bullish 2026 forecast, and doubles down on AI with key acquisitions.

A new partnership brings AI to customs, promising to help U.S. importers reclaim millions in overpaid duties and navigate volatile global trade.

Spectral Medical shifts its FDA submission for a breakthrough sepsis device, a strategic move that could strengthen its case but delays a potential lifeline.

Robert Herjavec invests in AI firm Lovelytics, betting on the critical need for data infrastructure and aiming to scale the top Databricks partner.

As a 24-year CEO era ends, McCoy Global bets on an internal tech architect to lead its future in automated well construction and maintain growth.

As Matricelf presents its breakthrough therapy at a major summit, the company moves closer to human trials, offering new hope for paralysis patients.

Romania's new 1,500km quantum network, powered by IonQ, marks a major step in Europe's race to secure critical data against future cyber threats.

With promising data for its oral STAT6 degrader and a cash runway into 2029, Kymera Therapeutics is poised to disrupt the injectable-dominated market.

Former USAA CEO Wayne Peacock joins Cotality's board, signaling a strategic push to lead the AI-driven property data and insurance analytics market.

A new partnership aims to capitalize on surging defense spending and supply chain shifts, signaling a new era for specialized private equity investing.

Kairos Pharma aims to reshape lung cancer treatment by acquiring two AI-designed drugs, targeting a key resistance mechanism in a multi-billion dollar market.

After a massive divestiture, Vistance Networks reports soaring growth, zero debt, and plans a huge special cash distribution to its shareholders.

Facing slow auto OEM cycles, Arbe Robotics names a new CEO and targets defense, robotaxis, and China to accelerate revenue from its high-res radar tech.

With a key FDA decision looming and pivotal data on a second therapy imminent, Viridian is poised to reshape the multi-billion dollar Thyroid Eye Disease market.

After a strong 2025, Viatris unveils a plan for $650M in savings, a 10% workforce cut, and a focus on six new drugs to fuel future innovation.